Diamonds DisruptED Pt. 2

Listeners and viewers, welcome back to another episode of DisruptED. If you missed the first episode with Amish Shah, founder and CEO of ALTR and J’evar, I highly recommend going back to hear his incredible entrepreneurial journey.

Amish Shah, hailing from a traditional Indian family with a long history in the diamond business, decided to carve a different path in the diamond industry. Despite his family’s expectations to continue their legacy, Amish was driven by a passion for technology. His journey reached a significant milestone in 2016 with the first commercial sale of lab-grown diamonds.

In June 2016, exactly ten years after his initial attempt, Amish presented lab-grown diamonds at a major trade show. His efforts paid off when a prominent jewelry store in Omaha, owned by Berkshire, decided to showcase his products, empowering consumers with a choice. The success was swift, with sales increasing eightfold within eight months, driven purely by consumer education rather than traditional advertising.

By 2017, ALTR’s lab-grown diamonds had gained significant traction, leading to a partnership with Helzberg Diamonds. Within the first 30 days, ALTR broke sales records, prompting further expansion. In 2018, they unveiled the world’s first lab-grown pink diamond, marking another significant achievement.

A key innovation by Amish was the introduction of e-certification for grading reports, replacing the traditional paper and plastic system. This move towards sustainability and transparency revolutionized the diamond industry’s supply chain and has since become a standard practice.

Amish’s impact on the diamond industry extends beyond consumer jewelry. Recognizing the broader applications of lab-grown diamonds, the Indian government has invested $30 million in research, aiming to leverage these diamonds for industrial and technological advancements. This initiative could transform sectors from water purification to defense.

In a symbolic gesture, Indian Prime Minister Narendra Modi gifted a lab-grown diamond to President Joe Biden, highlighting India’s commitment to this innovative technology.

Amish Shah’s journey is a testament to the power of innovation and disruption in a traditional industry. Stay tuned for our next episode, where we will delve deeper into the industrial applications of lab-grown diamonds and their potential to transform various sectors. Until then, keep disrupting!

Follow us on social media for the latest updates in B2B!

Image

Latest

personal branding
Personal Branding Now Drives B2B Success, Customer Trust, and Competitive Advantage
December 5, 2025

Personal branding has rapidly shifted from a “nice-to-have” to a strategic imperative in B2B marketing, reshaping how companies communicate, differentiate, and build trust. As industries evolve and professionals take on more dynamic, multi-stream careers, visibility and authenticity have become critical assets. Key findings from the Edelman + LinkedIn Thought Leadership Impact Report show that…

Read More
IT
Real-World IT Practices Are Streamlining AV Deployments and Raising the Bar for Consistency
December 4, 2025

For years, the AV industry has discussed the long-anticipated convergence with IT—but that shift is no longer theoretical. With cloud adoption accelerating, hybrid work normalizing, and organizations rebuilding digital infrastructure after years of rapid change, AV systems now sit squarely on the IT backbone. In fact, the majority of newly upgraded conference rooms require network-centric…

Read More
ROI
ROI Case Study
December 3, 2025

Denials are no longer a slow leak in the revenue cycle—they’re a fast-moving, rule-shifting game controlled by payers, and hospitals that don’t model denial patterns in real time end up budgeting around losses they could have prevented. PayerWatch’s four-digit, client-verified ROI in 2024 shows what happens when a hospital stops reacting claim by…

Read More
coverage
Clip 2 – Fighting for Coverage: One Patient’s Story
December 3, 2025

Health insurers love to advertise themselves as guardians of care, but the real story often begins when a patient’s life no longer fits neatly into a spreadsheet. In oncology especially, “coverage” isn’t a bureaucratic checkbox—it’s the fragile bridge between a treatment that finally works and a relapse that can undo years of grit…

Read More